Biotech Names to Watch: Amgen and AVI
Amgen stays strong, AVI emerging from consolidation. Hear Bill and the committee’s take on these biotech names and what could happen next. Segment begins with Bill Baruch at 2:28 Discover Blue Line Capital Ready to explore how Blue Line Capital can help you achieve your financial goals? Let’s chat! Click the button to get started.
Trade Tracker: Bill Baruch buys more Amgen
Bill Baruch, founder and president at Blue Line Capital, joins CNBC’s “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector. Discover Blue Line Capital Ready to explore how Blue Line Capital can help you achieve your financial goals? Let’s chat! Click the button to get started.
Why is Blue Line Increasing AAPL and AMGN?
Discover the latest insights on Apple and Amgen’s recent developments from market expert Bill Baruch.